

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on June 30, 1999  
By: Nancy L. Glynn  
Printed: 7/17/99



II12  
Docket No.: PF-0126-1 DIV

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bandman et al.

Title: A NOVEL TUMOR PROTEIN

Serial No.: 09/162,597

Filing Date: September 29, 1998

Examiner: N. Johnson

Group Art Unit: 1642

RECEIVED  
JUL 13 1999  
TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

### AMENDMENT TRANSMITTAL FEE SHEET

Sir:

Transmitted herewith are the following for the above-identified application:

1. Return Receipt Postcard;
2. Response (4 pp.); and
3. Revocation and Power of Attorney (2 pp.).

The fee has been calculated as shown below.

| Claims  | Claims<br>After<br>Amendment | - | Claims<br>Previously<br>Paid For | = | Present<br>Extra | Other Than<br>Small Entity<br>Rate | Additional<br>Fee(s) |
|---|------------------------------|---|----------------------------------|---|------------------|------------------------------------|----------------------|
| Total<br>Claims                                       | 6                            | - | 20                               | = | 0                | \$22                               | \$0                  |
| Indep.<br>Claims                                      | 1                            | - | 3                                | = | 0                | \$82                               | \$0                  |
| <u>First Presentation of Multiple Dependent Claim</u> |                              |   |                                  |   |                  | +\$270                             | \$                   |

X TOTAL \$ 0

       No additional fee is required.  
       Please charge Incyte Pharmaceuticals, Inc. Deposit  
Account No. 09-0108 the amount of \$       

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Incyte Pharmaceuticals, Inc. Deposit Account No. 09-0108. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Danielle M. Pasqualone

Danielle M. Pasqualone, Ph.D.

Reg. No. 43,847

Date: 29 June 1999  
3174 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 845-4892 Fax: (650) 849-8886